The Oxford and AstraZeneca Covid-19 vaccine candidate’s late-stage trial results are “really exciting” but more work needs to be done, said Professor Andrew Pollard on Monday.
Phase III trial results found it was 90% effective if administered at a half dose and then at a full dose, or 62% effective if administered in two full doses.
For the latest developments, click here:
Subscribe to The Telegraph on YouTube ►
Get the latest headlines:
Telegraph.co.uk and YouTube.com/TelegraphTV are websites of The Telegraph, the UK’s best-selling quality daily newspaper providing news and analysis on UK and world events, business, sport, lifestyle and culture.
